Search the Newsreel

Mettler-Toledo International (NYSE:MTD) CFO Shawn Vadala Sells 2,240 Shares of Stock

Mettler-Toledo International (NYSE:MTD) CFO Shawn Vadala recently sold 2,240 shares of the company's stock for over $3.2 million, reducing his direct holdings by 28.65%. This transaction comes as the company reported better-than-expected quarterly earnings with an EPS of $11.46 and revenue of $1.03 billion, …

Mettler Toledo International Insider Sold Shares Worth $342,514, According to a Recent SEC Filing

An insider at Mettler Toledo International recently sold shares valued at $342,514, as detailed in a recent SEC filing. This transaction involved a significant sale of company stock by an insider. The specific details of the sale are publicly available through the SEC filing.

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

A senior source has denied any ongoing or historical discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting earlier speculation about a nearly $400 billion deal. The denial follows initial reports that caused AstraZeneca's shares to drop, with the subsequent denial …

No deal between AstraZeneca and BMS, senior source insists: Reuters

Reuters has reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb are false, according to a senior source close to the matter. This news deflates widespread speculation about what could have been the largest pharmaceutical deal in history, valued at approximately …

Gerry Keller At Mettler-Toledo Intl Capitalizes: Options Exercised, Resulting In $172K

Gerry Keller, Head Process Analytics at Mettler-Toledo Intl (NYSE: MTD), recently exercised stock options for 240 shares valued at $172,125. The company's financials show a positive revenue trend with a 4.48% growth rate but a high debt-to-equity ratio of 164.7. Mettler-Toledo Intl has a …

Mettler Toledo director Natalia Shuman-Fabbri files initial beneficial ownership statement

Mettler Toledo director Natalia Shuman-Fabbri has filed her initial Form 3 beneficial ownership statement, dated August 3. This news brief was generated by Public Technologies (PUBT) using AI and is based on original content published by Mettler Toledo International Inc. via the SEC's EDGAR …

Is Mettler-Toledo International (MTD) Fully Priced After A 18% Gain?

Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks

A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol Myers Squibb's stock …

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

A senior source close to the matter has stated that there are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on potential talks …

‘No discussions’ ongoing for AstraZeneca-BMS merger: Reuters

Reuters reported that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting an earlier Financial Times report. The Financial Times report had caused AstraZeneca's stock to drop, while the Reuters news led to a rebound for AZ …

Bristol-Myers falls on report there are no talks going on with AstraZeneca

Bristol-Myers Squibb's stock fell 1.4% in premarket trading following a report that there are no ongoing discussions with AstraZeneca regarding a potential deal. Conversely, AstraZeneca's shares rose by 5.6% after the news. The report explicitly stated that no deal ever existed between the two …

Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75

Argus has upgraded Bristol-Myers Squibb (BMY) to a "Buy" rating from "Hold," setting a new price target of $75. The company currently holds an average rating of "overweight" with a mean price target of $66 among analysts. The full MT Newswires article with further …

Noida Toll Bridge net profit rises 26% in Q1FY26 on other income

Bristol-Myers Squibb Co (BMY) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Autolus Raises AUCATZYL Outlook, Secures New Credit Facility

Autolus Therapeutics has raised its full-year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, following strong second-quarter sales and improved operational efficiencies. The company also secured a five-year, interest-only senior credit facility of up to $250 million with Perceptive …

Mettler-Toledo International Inc. Just Recorded A 9.8% EPS Beat: Here's What Analysts Are Forecasting Next

Mettler-Toledo International Inc. recently reported a 9.8% EPS beat, surpassing analyst expectations. This article will likely discuss the company's latest financial results and provide insights into what analysts are predicting for Mettler-Toledo's future performance based on these strong earnings. It will likely cover key …

Latham & Watkins Advises Perceptive Advisors on Growth Financing for Leading Oncology Biotech Autolus Therapeutics

Latham & Watkins LLP advised Perceptive Advisors on a senior secured notes facility of up to US$250 million for Autolus Therapeutics plc. The financing includes an initial US$75 million, with additional funds available based on Autolus's options and revenue milestones. This funding, combined with …

AstraZeneca and Bristol Myers Squibb Held Merger Talks | PharmExec

AstraZeneca and Bristol Myers Squibb recently held discussions about a potential merger that would create the world's largest pharmaceutical company by revenue, with a combined market capitalization of nearly $400 billion. The report, though unconfirmed by either company, led to a drop in AstraZeneca …

Baron Capital Added to Mettler-Toledo (MTD) After Its Sharp Decline

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Mettler-Toledo International (NYSE:MTD) Given New $1,450.00 Price Target at Morgan Stanley

Morgan Stanley has raised its price target for Mettler-Toledo International (NYSE:MTD) to $1,450.00 from $1,275.00, while maintaining an "equal weight" rating. This adjustment follows Mettler-Toledo's strong second-quarter earnings, where it surpassed EPS estimates with $11.46 and saw revenue grow by 4.5% year-over-year to $1.03 …

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’

Analysts are describing a potential merger between AstraZeneca and Bristol Myers Squibb as "odd," despite its potential to create a major cancer-drug powerhouse. The Financial Times reported early-stage talks, leading to AstraZeneca shares closing lower and Bristol Myers Squibb remaining flat. This merger would …

Bristol Myers Squibb, AstraZeneca reportedly weigh $400B merger

U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion merger. If successful, this tie-up would create the world’s fourth-largest drugmaker by market value and the largest by revenue, uniting their strengths in oncology, immunology, …

Pacer Advisors Inc. Has $29.86 Million Holdings in Autoliv, Inc. $ALV

Pacer Advisors Inc. significantly increased its stake in Autoliv, Inc. (NYSE:ALV) by 3,296.4% in the first quarter, now holding 283,973 shares valued at $29.86 million, representing about 0.38% of the company. Autoliv maintains a "Moderate Buy" consensus rating from analysts with an average price …

Toll Brothers Announces Model Home Grand Opening at Vintage Grove in Fuquay-Varina, North Carolina

Toll Brothers announced the grand opening of its new model home at Vintage Grove in Fuquay-Varina, North Carolina, on August 8. The community features 46 luxury homes on oversized sites, with the model showcasing a Rosella design with 5 bedrooms, 5.5 baths, a 3-car …

Toll Brothers Announces Haven at Sea Bright is Now Open on the New Jersey Coast

Toll Brothers has announced the grand opening of Haven at Sea Bright, a new luxury home community in Sea Bright, New Jersey. The community offers single-family homes and townhomes with water views, ranging from 2,467 to over 3,000 square feet, and is priced from …

Empowered Funds LLC Has $3.43 Million Holdings in Mettler-Toledo International, Inc. $MTD

Empowered Funds LLC significantly increased its stake in Mettler-Toledo International, Inc. (NYSE:MTD) by 63.9% in the first quarter, bringing its total holdings to $3.43 million. Other institutional investors also adjusted their positions, and the company recently reported strong Q2 earnings that surpassed expectations, leading …

Autolus Therapeutics (AUTL) Projected to Release Quarterly Earnings on Tuesday

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?

Mettler Toledo International (MTD) Could Be 4% Overvalued As Strong Earnings Reignite Interest

Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?

BioNTech Aktie: BNT327 mit Bristol Myers Squibb

Noida Toll Bridge Q1 FY27: Profit Surge Masks Deeper Structural Concerns

Tolu Minerals (ASX:TOK): Gold and Copper Development Strategy Gains Market Attention

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb have been met with skepticism and a significant stock sell-off on Wall Street. Analysts are perplexed by AstraZeneca's interest, given its strong organic growth, while Bristol Myers faces patent expirations for key products. …

Piper Sandler Maintains Capitol Federal Financial(CFFN.US) With Hold Rating, Raises Target Price to $9.5

Piper Sandler has reiterated its Hold rating on Capitol Federal Financial (CFFN.US) and increased its target price for the stock to $9.5. This indicates a maintained neutral stance with a slightly more optimistic outlook on the stock's future value.

What Toll Brothers (TOL)'s Luxury Community and Design Studio Expansion Means For Shareholders

Toll Brothers has expanded its luxury communities and Design Studio network across multiple U.S. states, offering high-end homes and resort-style amenities. This strategy reinforces its brand as a customizable, lifestyle-focused builder, which is a key part of its investment narrative. While this expansion supports …